AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2679244 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur tablets (200 mg theophylline anhydrous sustained-release) taken in the evening without food
Number of subjects: 0
Study 1211837 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mm diameter metal cannula
Number of subjects: 300
Study 1211837 — intervention group
Group type: COMPARATOR
Intervention: Flexible plastic cannula
Number of subjects: 300
Study 31504091 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment with no choice
Number of subjects: 117
Study 31504091 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment with choice (single or daily)
Number of subjects: 117
Study 31504091 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 117
Study 31237547 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG without carbohydrate preoperative oral feeding
Number of subjects: 80
Study 31237547 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG with carbohydrate preoperative oral feeding
Number of subjects: 80
Study 31237547 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG without carbohydrate preoperative oral feeding
Number of subjects: 80
Study 31237547 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG with carbohydrate preoperative oral feeding
Number of subjects: 80
Study 28192584 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-based scanned capsule centration (SCC) with three-piece IOL
Number of subjects: 160
Study 28192584 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-based scanned capsule centration (SCC) with plate-haptic IOL
Number of subjects: 160
Study 28192584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupil centration (PC) with three-piece IOL
Number of subjects: 160
Study 28192584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupil centration (PC) with plate-haptic IOL
Number of subjects: 160
Study 25490004 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum sensitive
Number of subjects: 329
Study 25490004 — intervention group
Group type: COMPARATOR
Intervention: Refractory
Number of subjects: 329
Study 25490004 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum lactate dehydrogenase
Number of subjects: 329
Study 25490004 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 329
Study 25490004 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status of 1
Number of subjects: 329
Study 25490004 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss ≥ 5%
Number of subjects: 329
Study 25490004 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum sensitivity status
Number of subjects: 329
Study 25490004 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum sensitivity status excluding 36 patients with multiple prior regimens
Number of subjects: 329
Study 23857420 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (those who returned questionnaires)
Number of subjects: 194
Study 23857420 — intervention group
Group type: COMPARATOR
Intervention: Non-responders (those who did not return questionnaires)
Number of subjects: 194
Study 23857420 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (responders and non-responders)
Number of subjects: 194
Study 20670468 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Lactobacillus casei strain Shirota
Number of subjects: 3758
Study 20670468 — intervention group
Group type: COMPARATOR
Intervention: Nutrient drink
Number of subjects: 3758
Study 20670468 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink
Number of subjects: 3758
Study 19374155 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mL/kg ropivacaine 0.75% (group R)
Number of subjects: 60
Study 19374155 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mL/kg saline 0.9% (group F)
Number of subjects: 60
Study 17426611 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 different interventions
Number of subjects: 1
Study 17426611 — intervention group
Group type: COMPARATOR
Intervention: Full-factorial design
Number of subjects: 1
Study 14768298 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 0
Study 14768298 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 0
Study 14768298 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 0
Study 11465587 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) combined with physical therapy (PT)
Number of subjects: 54
Study 11465587 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 54
Study 9488072 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate
Number of subjects: 0
Study 9488072 — intervention group
Group type: COMPARATOR
Intervention: Transurethral incision of the prostate
Number of subjects: 0
Study 7961547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (type IA antiarrhythmics)
Number of subjects: 0
Study 7961547 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I antiarrhythmic drugs
Number of subjects: 0
Study 7961547 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin selective reuptake inhibitors or bupropion
Number of subjects: 0
Study 3288434 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.14% sodium monofluorophosphate (1500 ppm F) dentifrice
Number of subjects: 2415
Study 3288434 — intervention group
Group type: COMPARATOR
Intervention: 0.76% sodium monofluorophosphate (1000 ppm F) dentifrice
Number of subjects: 2415
Study 30005049 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg teriparatide (PTH)
Number of subjects: 87
Study 30005049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 27580156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC)
Number of subjects: 18
Study 27580156 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham Intervention (SHAM)
Number of subjects: 18
Study 27580156 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 18
Study 27580156 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (IPC, SHAM, CT)
Number of subjects: 18
Study 28638192 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural therapy (12 weeks, 3 times a week, 90 minutes per session)
Number of subjects: 110
Study 28638192 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal medications only)
Number of subjects: 110
Study 25536255 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive care
Number of subjects: 201
Study 25536255 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 201
Study 22903151 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 22903151 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based approach
Number of subjects: 0
Study 22903151 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise trial
Number of subjects: 0
Study 19244038 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertain diagnosis group (73 patients)
Number of subjects: 150
Study 19244038 — intervention group
Group type: COMPARATOR
Intervention: Known benign group (37 patients)
Number of subjects: 150
Study 19244038 — intervention group
Group type: COMPARATOR
Intervention: Known malignant group (16 patients)
Number of subjects: 150
Study 17295900 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic TNF‐α and IFN‐γ levels in pregnant women (n = 51)
Number of subjects: 126
Study 17295900 — intervention group
Group type: COMPARATOR
Intervention: Systemic TNF‐α and IFN‐γ levels in not pregnant women (n = 75)
Number of subjects: 126
Study 17295900 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic TNF‐α and IFN‐γ levels in women who miscarried (n = 13)
Number of subjects: 126
Study 17295900 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic TNF‐α and IFN‐γ levels in women who had a live birth (n = 38)
Number of subjects: 126
Study 17295900 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic TNF‐α and IFN‐γ levels in women with high activated NK cells (n = 39)
Number of subjects: 126
Study 17295900 — intervention group
Group type: COMPARATOR
Intervention: Systemic TNF‐α and IFN‐γ levels in women with low activated NK cells (n = 87)
Number of subjects: 126
Study 15449653 — intervention group
Group type: EXPERIMENTAL
Intervention: Radish containing diet
Number of subjects: 36
Study 15449653 — intervention group
Group type: COMPARATOR
Intervention: Self‐selected diet
Number of subjects: 36
Study 11794743 — intervention group
Group type: EXPERIMENTAL
Intervention: Linseed extract Salinum alone (Sal)
Number of subjects: 22
Study 11794743 — intervention group
Group type: EXPERIMENTAL
Intervention: Linseed extract Salinum with chlorhexidine (Sal/Chx)
Number of subjects: 22
Study 9684641 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (8.5 mg/kg of body weight/day for 60 days)
Number of subjects: 404
Study 9684641 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (6 mg/kg of body weight/day for 120 days)
Number of subjects: 404
Study 9684641 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pure starch)
Number of subjects: 404
Study 9684641 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 404
Study 9684641 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 404
Study 7798370 — intervention group
Group type: EXPERIMENTAL
Intervention: Extremely low birth weight (ELBW) children
Number of subjects: 1868
Study 7798370 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with IQ scores above 85
Number of subjects: 1868
Study 3182592 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (200 mg)
Number of subjects: 23
Study 3182592 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (4 mg)
Number of subjects: 23
Study 3182592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (24 mg)
Number of subjects: 23
Study 3182592 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (10 mg)
Number of subjects: 23
Study 3182592 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (1:1000, 0.5 ml subcutaneously)
Number of subjects: 23
Study 31637577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg
Number of subjects: 0
Study 31637577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg
Number of subjects: 0
Study 31637577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 20 mg
Number of subjects: 0
Study 31637577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27188890 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-behind children (LBC)
Number of subjects: 827
Study 27188890 — intervention group
Group type: COMPARATOR
Intervention: Non-left-behind children (non-LBC)
Number of subjects: 827
Study 24287370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosomal docetaxel lipid suspension (NDLS)
Number of subjects: 72
Study 24287370 — intervention group
Group type: COMPARATOR
Intervention: Taxotere (75 mg/m2)
Number of subjects: 72
Study 23179200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling + 30 g/day flaxseed supplementation (LCF)
Number of subjects: 173
Study 23179200 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle counseling (LC)
Number of subjects: 173
Study 20639722 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise training (A group)
Number of subjects: 251
Study 20639722 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise training (R group)
Number of subjects: 251
Study 20639722 — intervention group
Group type: COMPARATOR
Intervention: Combined aerobic and resistance training (A + R group)
Number of subjects: 251
Study 20639722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary lifestyle (C group)
Number of subjects: 251
Study 18981208 — intervention group
Group type: EXPERIMENTAL
Intervention: Audience Response System (ARS)
Number of subjects: 77
Study 18981208 — intervention group
Group type: COMPARATOR
Intervention: Conventional lectures
Number of subjects: 77
Study 15640601 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% citrate lock
Number of subjects: 28
Study 15640601 — intervention group
Group type: COMPARATOR
Intervention: 10% citrate lock
Number of subjects: 28
Study 12531794 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP with G-CSF
Number of subjects: 455
Study 12531794 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP without G-CSF
Number of subjects: 455
Study 12531794 — intervention group
Group type: EXPERIMENTAL
Intervention: CNOP with G-CSF
Number of subjects: 455
Study 12531794 — intervention group
Group type: EXPERIMENTAL
Intervention: CNOP without G-CSF
Number of subjects: 455
Study 12531794 — intervention group
Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 455
Study 12531794 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP
Number of subjects: 455
Study 12531794 — intervention group
Group type: COMPARATOR
Intervention: CNOP
Number of subjects: 455
Study 10812254 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 60
Study 10812254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8668508 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate order of reporting stimulus-dimension values
Number of subjects: 0
Study 8668508 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical identification
Number of subjects: 0
Study 8668508 — intervention group
Group type: COMPARATOR
Intervention: Identification of meaning
Number of subjects: 0
Study 8668508 — intervention group
Group type: COMPARATOR
Intervention: Redundant color coding
Number of subjects: 0
Study 8668508 — intervention group
Group type: COMPARATOR
Intervention: Stimulus location
Number of subjects: 0
Study 8668508 — intervention group
Group type: COMPARATOR
Intervention: Difficulty of the dual task
Number of subjects: 0
Study 8214043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion (10%; 30 ml/h)
Number of subjects: 7
Study 8214043 — intervention group
Group type: COMPARATOR
Intervention: Control (0.154 mol/l NaCl)
Number of subjects: 7
Study 3767596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tryptophan
Number of subjects: 44
Study 3767596 — intervention group
Group type: COMPARATOR
Intervention: Long-term alprazolam treatment
Number of subjects: 44
Study 30220368 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported perceived exertion with automatic internet-based feedback
Number of subjects: 0
Study 30220368 — intervention group
Group type: COMPARATOR
Intervention: IMT with 30% maximal inspiratory pressure without feedback
Number of subjects: 0
Study 24366521 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 sexual health phone counseling contacts over 24 months
Number of subjects: 701
Study 24366521 — intervention group
Group type: COMPARATOR
Intervention: 12 general health phone counseling contacts over 24 months
Number of subjects: 701
Study 22994875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide
Number of subjects: 12
Study 22994875 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 12
Study 22994875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide/Voglibose combination
Number of subjects: 12
Study 22994875 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 12
Study 19747792 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate transfer for percutaneous coronary intervention (PCI)
Number of subjects: 266
Study 19747792 — intervention group
Group type: COMPARATOR
Intervention: Standard management in local hospitals (conservative group)
Number of subjects: 266
Study 19747792 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate transfer for PCI
Number of subjects: 266
Study 17921388 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilenje Baby Mix (CBM); energy density: 68 kcal/100 g; n = 37
Number of subjects: 150
Study 17921388 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilenje Baby Mix with alpha-amylase (CBMA); energy density: 106 kcal/100 g; n = 44
Number of subjects: 150
Study 17921388 — intervention group
Group type: COMPARATOR
Intervention: Control group; n = 69
Number of subjects: 150
Study 16150805 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab + chemotherapy (doxorubicin/cyclophosphamide or paclitaxel)
Number of subjects: 0
Study 16150805 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine + trastuzumab
Number of subjects: 0
Study 16150805 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab-based therapy
Number of subjects: 0
Study 16150805 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 gene amplification
Number of subjects: 0
Study 12383299 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP laser tonsillectomy
Number of subjects: 151
Study 12383299 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection tonsillectomy
Number of subjects: 151
Study 10653049 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (50/500 microg) via a single Diskus inhaler (combination)
Number of subjects: 503
Study 10653049 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg and fluticasone propionate 500 microg administered via separate Diskus inhalers (concurrent)
Number of subjects: 503
Study 10653049 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 500 microg and placebo
Number of subjects: 503
Study 7608448 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 25 mg/day
Number of subjects: 166
Study 7608448 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day
Number of subjects: 166
Study 7608448 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg/day
Number of subjects: 166
Study 2496815 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 20
Study 2496815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 998551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplements
Number of subjects: 0
Study 998551 — intervention group
Group type: COMPARATOR
Intervention: Control (no dietary supplements)
Number of subjects: 0
Study 30608989 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation levels of CADM1, FAM19A4, and MAL in cytologic HSIL
Number of subjects: 260
Study 30608989 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation levels of CADM1, FAM19A4, and MAL in histologic HSIL+
Number of subjects: 260
Study 30608989 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM19A4 methylation for differentiating high-grade cytology
Number of subjects: 260
Study 30608989 — intervention group
Group type: EXPERIMENTAL
Intervention: CADM1 methylation for distinguishing histologic HSIL+
Number of subjects: 260
Study 30608989 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined high DNA methylation levels with HPV16/18 genotypes
Number of subjects: 260
Study 29184891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone equipped with FrontlineSMS based application in intervention woredas (Ezha and Abeshge)
Number of subjects: 3240
Study 29184891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone equipped with FrontlineSMS based application in Ezha woreda
Number of subjects: 3240
Study 29184891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone equipped with FrontlineSMS based application in all intervention woredas
Number of subjects: 3240
Study 29184891 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mobile intervention)
Number of subjects: 3240
Study 26212846 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified sleep restriction (SSR)
Number of subjects: 97
Study 26212846 — intervention group
Group type: COMPARATOR
Intervention: Control (sleep hygiene advice alone)
Number of subjects: 97
Study 23329119 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 25
Study 23329119 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression group
Number of subjects: 25
Study 23329119 — intervention group
Group type: EXPERIMENTAL
Intervention: Stability group
Number of subjects: 25
Study 22145506 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable vacuum dressing
Number of subjects: 30
Study 22145506 — intervention group
Group type: COMPARATOR
Intervention: Conventional wall vacuum dressing
Number of subjects: 30
Study 19506005 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based task-oriented exercise programme (sit-to-stand and step-up exercise) for six weeks
Number of subjects: 20
Study 19506005 — intervention group
Group type: COMPARATOR
Intervention: Regular daily activities
Number of subjects: 20
Study 17045894 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFA) 2 g/die
Number of subjects: 25
Study 17045894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12740675 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg sodium hyaluronate (Na HA)
Number of subjects: 60
Study 12740675 — intervention group
Group type: COMPARATOR
Intervention: 40 mg 6‐methylprednisolone acetate (6‐MPA)
Number of subjects: 60
Study 11126257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (200 mg/ml) intravenously as a bolus injection (0.5 ml/kg) over 10 min and thereafter as a continuous intravenous infusion (90 ml/h) for 4 h combined with heparin (200 U/h)
Number of subjects: 11
Study 11126257 — intervention group
Group type: COMPARATOR
Intervention: Saline instead of Intralipid and heparin
Number of subjects: 11
Study 9133082 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (control)
Number of subjects: 539
Study 9133082 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CMF modality)
Number of subjects: 539
Study 9133082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (Tam)
Number of subjects: 539
Study 9133082 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with CMF and Tam
Number of subjects: 539
Study 9133082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 539
Study 9133082 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol
Number of subjects: 539
Study 8329784 — intervention group
Group type: EXPERIMENTAL
Intervention: Four temazepam 7.5‐mg capsules
Number of subjects: 26
Study 8329784 — intervention group
Group type: COMPARATOR
Intervention: One temazepam 30‐mg capsule
Number of subjects: 26